← Back to Search

Macrolide Antibiotic

Clarithromycin for Excessive Daytime Sleepiness

Phase 2
Recruiting
Led By Lynn Marie Trotti, MD, MSc
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of idiopathic hypersomnia or narcolepsy
diagnosis of idiopathic hypersomnia or narcolepsy type 2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day -2, day 13
Awards & highlights

Study Summary

This trial is evaluating whether the drug clarithromycin can help reduce sleepiness in people with narcolepsy or idiopathic hypersomnia.

Who is the study for?
This trial is for adults aged 18-60 with narcolepsy or idiopathic hypersomnia who are either not taking wake-promoting meds, can stop them safely before the study, or still feel sleepy on these meds. They shouldn't have taken pre/probiotic supplements for six months and must not have other sleep disorders or conditions that could explain their sleepiness.Check my eligibility
What is being tested?
Researchers are testing clarithromycin against a placebo to see if it reduces sleepiness in those with narcolepsy and idiopathic hypersomnia. The study will also explore how this drug affects brain activity, inflammation, gut bacteria, and cerebrospinal fluid by using MRI scans among other methods.See study design
What are the potential side effects?
Clarithromycin may cause side effects like digestive issues (nausea, diarrhea), changes in taste sensation, headaches, and rarely more serious conditions such as allergic reactions or liver problems. Side effects vary from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with idiopathic hypersomnia or narcolepsy.
Select...
I have been diagnosed with idiopathic hypersomnia or narcolepsy type 2.
Select...
I am between 18 and 60 years old.
Select...
I am between 18 and 60 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day -2, day 13
This trial's timeline: 3 weeks for screening, Varies for treatment, and day -2, day 13 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Default Mode Network (DMN) Connectivity
Change in Epworth Sleepiness Scale Score
Change in Maintenance of Wakefulness Test (MWT)
+3 more
Secondary outcome measures
Change in Fatigue Severity Scale (FSS) Score
Change in Functional Outcomes of Sleep Questionnaire (FOSQ) Score
Change in Hypersomnia Severity Index (HSI)
+15 more

Side effects data

From 2021 Phase 3 trial • 1046 Patients • NCT04167670
5%
Diarrhoea
1%
Dysgeusia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vonoprazan Dual Therapy
Vonoprazan Triple Therapy
Lansoprazole Triple Therapy

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ClarithromycinExperimental Treatment1 Intervention
Participants in this study arm will receive clarithromycin for 14 days.
Group II: PlaceboPlacebo Group1 Intervention
Participants in this study arm will receive a placebo to match clarithromycin for 14 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clarithromycin
2017
Completed Phase 4
~3950

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,638 Previous Clinical Trials
2,560,450 Total Patients Enrolled
1 Trials studying Idiopathic Hypersomnia
44 Patients Enrolled for Idiopathic Hypersomnia
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,340 Previous Clinical Trials
649,269 Total Patients Enrolled
Lynn Marie Trotti, MD, MSc4.29 ReviewsPrincipal Investigator - Emory University
Emory University
1 Previous Clinical Trials
44 Total Patients Enrolled
1 Trials studying Idiopathic Hypersomnia
44 Patients Enrolled for Idiopathic Hypersomnia
5Patient Review
Dr. So-and-so is very knowledgeable about sleep disorders and easy to communicate with. I appreciate that she values my input in regards to how my care progresses.

Media Library

Clarithromycin (Macrolide Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT04026958 — Phase 2
Idiopathic Hypersomnia Research Study Groups: Placebo, Clarithromycin
Idiopathic Hypersomnia Clinical Trial 2023: Clarithromycin Highlights & Side Effects. Trial Name: NCT04026958 — Phase 2
Clarithromycin (Macrolide Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04026958 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current capacity of participants in this clinical venture?

"Affirmative, clinicaltrials.gov indicates that this medical experiment is now enlisting participants. This study was initially broadcasted on September 4th 2019 and has since been revised on June 15th 2022. The team behind the trial currently needs 92 individuals across 1 site to complete the research project."

Answered by AI

Are elderly individuals being admitted to this clinical trial?

"As per the trial's eligibility requirements, participants must fall between 18 and 60 years old to be included."

Answered by AI

What risks do patients incur when taking Clarithromycin?

"While the efficacy of Clarithromycin is not yet confirmed, there are existing studies that support its safety. Thus, it received an approximate rating of 2 on our scale."

Answered by AI

Are recruitment efforts underway for this trial?

"As indicated by the clinicaltrials.gov database, this venture is recruiting participants at present. This trial was initially posted on September 4th 2019 and has been modified as recently as June 15th 2022."

Answered by AI

Who meets the prerequisites to join this investigation?

"This research is seeking 92 participants with idiopathic hypersomnia aged 18-60. In order to be considered, patients must have no wake-promoting medications in their system, narcolepsy type 2 or related diagnosis of the condition, not taken prebiotics/probiotics for 6 months prior to baseline measures and able to cease use of any current medication if applicable."

Answered by AI

What medical conditions can Clarithromycin be employed to address?

"Clarithromycin is normally used to combat bacterial infections, yet it can also be prescribed for mycobacterial sicknesses, hiv and acute cases of bronchitis."

Answered by AI

What results is the team hoping for from this experiment?

"The primary aim of this two week study is to measure any shifts in the gastrointestinal microbiome. Additionally, we are measuring changes in interleukin 1 alpha (IL-1α), interleukin 8 (IL-8), and interferon alpha (INF-α) levels which may correlate with a reduction in soporific cytokines leading to reduced daytime sleepiness."

Answered by AI

Who else is applying?

What state do they live in?
New York
Pennsylvania
Texas
How old are they?
65+
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
3+
Recent research and studies
clinicaltrials.govStudy
Clarithromycin Mechanisms in Hypersomnia Syndromes
Lynn Marie Trotti 2019. "Clarithromycin Mechanisms in Hypersomnia Syndromes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04026958.
All > Narcolepsy > Idiopathic Hypersomnia
~3 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top